HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text

Medicine, Oncology, Pathology +15

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy et al. · Journal of Clinical Oncology · 2020 · 817 citations · Full text

Medicine, Oncology, Pharmacology +17

Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute

Kenneth W. Hance, William F. Anderson, Susan S. Devesa et al. · JNCI Journal of the National Cancer Institute · 2005 · 702 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini, Núria Chic, Fara Brasó‐Maristany et al. · npj Breast Cancer · 2021 · 691 citations · Full text

Medicine, Cancer Biology, Oncology +10